Intrinsic Value of S&P & Nasdaq Contact Us

Biodexa Pharmaceuticals Plc BDRX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • GB • USD

SharesGrow Score
27/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Biodexa Pharmaceuticals Plc (BDRX) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

Analysts estimate Earnings Per Share (EPS) of $-0.01 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-1,157,000.00 vs est $-0.01 (missed -22051452017.7%). Analyst accuracy: 0%.

EPS Estimates — BDRX

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$1,157,000.00 vs Est –$0.01 ▼ 100.0% off
2025 Actual $0.00 vs Est –$0.00 ▲ 0.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS trend is improving.

Revenue Estimates — BDRX

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message